Merck scientists published a biocatalytic synthesis route to enlicitide ↗ in Science on May 7, replacing the conventional protecting-group chemistry used for macrocyclic peptide manufacture with a cascade of engineered enzymes that handles fragment formation, peptide coupling, and ring closure in sequence. The route cuts the number of synthetic steps by more than half versus the prior state-of-the-art and removes the need for column chromatography, the workhorse purification technique that has long been the cost and throughput bottleneck for large peptide drugs.
Enlicitide decanoate is Merck's investigational oral PCSK9 inhibitor, a once-a-day pill in Phase 3 testing for atherosclerotic cardiovascular disease. PCSK9 is a liver protein that controls how many LDL receptors sit on liver-cell surfaces, and lowering its activity raises LDL clearance and drives down circulating cholesterol. The currently approved PCSK9 drugs, evolocumab and alirocumab, are antibodies given by subcutaneous injection every two to four weeks. Enlicitide would be the first oral PCSK9 inhibitor on the market, and its CORALreef Phase 3 program reported a 55.8 percent LDL-C reduction earlier in 2026, the cardiovascular efficacy headline that put the program on every cardiologist's calendar.
The chemistry context. Macrocyclic peptides are ring-shaped molecules that sit in a difficult middle band between conventional small-molecule drugs and biologic antibodies. They are large enough (roughly 500 to 2,000 daltons) to engage protein-protein interaction surfaces that small molecules cannot reach, but small enough to potentially cross cell membranes and be given orally, where antibodies cannot. The price of that property combination is synthesis difficulty. A typical macrocyclic peptide drug requires twenty to forty discrete reaction steps, with protecting groups added and removed at each step to keep the wrong reactive groups from interfering, and chromatographic purification at most stages to clean up unwanted side products. The industry calls it the "peptide CDMO bottleneck", and it is the single largest reason macrocyclic peptide programs are slow to scale.
What the Merck team did. They engineered four enzyme classes (peptide ligases, macrocyclases, and two coupling enzymes) to perform the chemistry that protecting groups normally manage. Because enzymes recognize specific amino acid sequences and stereochemistries, they can do selective coupling without first masking every other reactive group on the peptide. The cascade runs in water, at near-neutral pH, with the enzymes added and removed by simple filtration. Crystallizations replace chromatography for purification at every stage where the molecule is crystalline, which the Merck team optimized for. The combination produces enlicitide in roughly half the steps of the prior route and at a fraction of the solvent and reagent input.
Why this matters beyond enlicitide. Macrocyclic peptide drug programs in development today include obesity peptides like CagriSema and petrelintide ↗ that the news section has covered, oncology candidates from Bicycle Therapeutics and the rest of the bicyclic peptide field, and the oral GLP-1 architectures Coracle published as defensive prior art ↗ last week. Each of those programs faces the same synthesis-cost problem the Merck route addresses. The Science paper is a methodology demonstration, not a Merck-only tool: protein engineering of peptide-bond-forming enzymes is a portable capability, and other large-pharma manufacturing groups will be running their own cascades on their own macrocycle programs within a year or two. The Manchester team's enzymatic penicillin route ↗ on May 4 made the same generalization for beta-lactam antibiotics. Two papers in two weeks pointing at the same direction is not coincidence; it reflects the maturation of enzyme-engineering toolkits to a point where biocatalytic cascades can be built for individual drug targets in workable timelines.
The platform read. The macrocyclic peptide design space the Merck route enables is exactly the band the platform's anticancer corpus ↗ has been expanding into, with bicyclic and constrained-cycle peptides forming a growing share of the recent additions. Cheaper synthesis at scale lowers the cost of moving a candidate from in silico design to lab validation to preclinical testing, which is the bottleneck the platform's design space is most directly trying to compress. As biocatalytic cascades become more routine, the gap between what the design half can specify and what the wet-lab half can actually make narrows, which is the precondition for the platform's macrocyclic and constrained-peptide candidates getting tested at the rate the design tools can generate them.
What this is not. A clinical change. Enlicitide's Phase 3 efficacy and safety read out on the same timeline regardless of how it is made. What this is is a manufacturing change with cost and supply consequences across an entire drug modality, and the most concrete signal in months that the macrocyclic peptide field's synthesis bottleneck is starting to give way.